Market icon

Kailera Therapeutics IPO Closing Market Cap

Market icon

Kailera Therapeutics IPO Closing Market Cap

2.1B+ 52%

<1.7B 48%

1.7B–1.8B 47%

1.8B–1.9B 46%

Polymarket
NUEVO

2.1B+ 52%

<1.7B 48%

1.7B–1.8B 47%

1.8B–1.9B 46%

Polymarket
NUEVO

<1.7B

$0 Vol.

48%

1.7B–1.8B

$0 Vol.

47%

1.8B–1.9B

$0 Vol.

46%

1.9B–2.0B

$0 Vol.

24%

2.0B–2.1B

$0 Vol.

23%

2.1B+

$0 Vol.

52%

No IPO before June 2026

$0 Vol.

24%

This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.

This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.

As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".

Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.

It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.

If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.

The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.

If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.

The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.

In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$0
Fecha de finalización
17 abr 2026
Mercado abierto
Apr 14, 2026, 5:05 PM ET
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.

This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.

As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".

Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.

It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.

If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.

The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.

If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.

The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.

In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$0
Fecha de finalización
17 abr 2026
Mercado abierto
Apr 14, 2026, 5:05 PM ET
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.

Cuidado con los enlaces externos.

Preguntas frecuentes

"Kailera Therapeutics IPO Closing Market Cap" es un mercado de predicción en Polymarket con 7 resultados posibles donde los operadores compran y venden acciones según lo que creen que sucederá. El resultado líder actual es "2.1B+" con 52%, seguido de "<1.7B" con 48%. Los precios reflejan probabilidades en tiempo real de la comunidad. Por ejemplo, una acción cotizada a 52¢ implica que el mercado colectivamente asigna una probabilidad de 52% a ese resultado. Estas probabilidades cambian continuamente a medida que los operadores reaccionan a nuevos desarrollos. Las acciones del resultado correcto son canjeables por $1 cada una tras la resolución del mercado.

"Kailera Therapeutics IPO Closing Market Cap" es un mercado recién creado en Polymarket, lanzado el Apr 14, 2026. Como mercado nuevo, esta es tu oportunidad de ser uno de los primeros operadores en establecer las probabilidades y las señales de precio iniciales del mercado. También puedes guardar esta página en marcadores para seguir el volumen y la actividad de trading a medida que el mercado gana tracción.

Para operar en "Kailera Therapeutics IPO Closing Market Cap", explora los 7 resultados disponibles en esta página. Cada resultado muestra un precio actual que representa la probabilidad implícita del mercado. Para tomar una posición, selecciona el resultado que consideres más probable, elige "Sí" para operar a favor o "No" para operar en contra, introduce tu cantidad y haz clic en "Operar". Si tu resultado elegido es correcto cuando el mercado se resuelve, tus acciones de "Sí" pagan $1 cada una. Si es incorrecto, pagan $0. También puedes vender tus acciones en cualquier momento antes de la resolución.

El favorito actual para "Kailera Therapeutics IPO Closing Market Cap" es "2.1B+" con 52%, lo que significa que el mercado asigna una probabilidad de 52% a ese resultado. El siguiente resultado más cercano es "<1.7B" con 48%. Estas probabilidades se actualizan en tiempo real a medida que los operadores compran y venden acciones. Vuelve con frecuencia o guarda esta página en marcadores.

Las reglas de resolución para "Kailera Therapeutics IPO Closing Market Cap" definen exactamente qué debe ocurrir para que cada resultado sea declarado ganador, incluyendo las fuentes de datos oficiales utilizadas para determinar el resultado. Puedes revisar los criterios de resolución completos en la sección "Reglas" en esta página sobre los comentarios. Recomendamos leer las reglas cuidadosamente antes de operar, ya que especifican las condiciones exactas, casos especiales y fuentes.